Blog

Andrea Apolo: Very proud of Saad Atiq for presenting data at ASCO25

Andrea Apolo/X

Jun 3, 2025, 12:27

Andrea Apolo: Very proud of Saad Atiq for presenting data at ASCO25

Andrea Apolo, Director of the Bladder Cancer and Genitourinary Tumors Multidisciplinary Clinic at the National Cancer Institute, shared a post on X:

“Very proud of our own Saad Atiq National Cancer Institute senior fellow presenting data on the Prevalence of Histology-Agnostic Biomarkers in Pure Squamous Cell Carcinomas of the Bladder showing 1/3 of patients with TMB-High.”

Andrea Apolo highlighted new findings presented by Saad Atiq on histology-agnostic biomarkers in pure squamous cell carcinomas of the bladder. The data revealed that one-third of these patients exhibited TMB-High, indicating potential implications for targeted therapies.

More posts featuring Andrea Apolo.

Agnostic Biomarkers Andrea Apolo ASCO25 bladder cancer cancer fight against cancer Genitourinary tumors Global fight against cancer National Cancer Institute NCI OncoDaily Oncology Saad Atiq squamous cell carcinomas TMB-High

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL

15 Posts Not to Miss from the 4th Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment

15 Posts Not to Miss from the 2nd Day of ASCO 2025